Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2020 Sep 10

PMID 32910933

Citations 25

Authors

Zi-Ning Lei

Zhuo-Xun Wu

Shaowei Dong

Dong-Hua Yang

Litu Zhang

Zunfu Ke

Chang Zou

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases. Since the pandemic of the coronavirus disease 2019 (COVID-19), CQ and HCQ have been subjected to a number of in vitro and in vivo tests, and their therapeutic prospects for COVID-19 have been proposed. In this article, the applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed. The current trials and future potential of CQ and HCQ in combating COVID-19 are discussed.

Citing Articles

Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.

Hazan S, Vidal A, Hulscher N, Goudzwaard A, McCullough P, Steinberg A BMC Cardiovasc Disord. 2024; 24(1):710.

PMID: 39702045 PMC: 11657509. DOI: 10.1186/s12872-024-04376-y.

Sustainable Natural Deep Eutectic Solvent-Mediated Synthesis of Magnesium Zirconate Nanoparticles: A Photocatalyst for the Degradation of Anti-Viral Drug.

Sriram B, V A, Wang S, P J, George M Inorg Chem. 2024; 63(43):20705-20713.

PMID: 39393015 PMC: 11523255. DOI: 10.1021/acs.inorgchem.4c03383.

Effects of hydroxychloroquine on the mucosal barrier and gut microbiota during healing of mice colitis.

Huang P, Zhou Y, Wang S, Qian X, Ren C, Zhou Z Am J Transl Res. 2024; 16(8):4144-4153.

PMID: 39262712 PMC: 11384370. DOI: 10.62347/FTYJ6152.

Pharmacology Progresses and Applications of Chloroquine in Cancer Therapy.

Liu Y, Meng Y, Zhang J, Gu L, Shen S, Zhu Y Int J Nanomedicine. 2024; 19:6777-6809.

PMID: 38983131 PMC: 11232884. DOI: 10.2147/IJN.S458910.

Evaluation of Dihydroartemisinin-Piperaquine Efficacy and Molecular Markers in Uncomplicated Falciparum Patients: A Study across Binh Phuoc and Dak Nong, Vietnam.

Tran T, Hien B, Dung N, Huong N, Binh T, Van Long N Medicina (Kaunas). 2024; 60(6).

PMID: 38929629 PMC: 11205605. DOI: 10.3390/medicina60061013.

References

Akpovwa H . Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct. 2016; 34(4):191-6. PMC: 5071688. DOI: 10.1002/cbf.3182. View

Mohandas N, An X . Malaria and human red blood cells. Med Microbiol Immunol. 2012; 201(4):593-8. PMC: 3699179. DOI: 10.1007/s00430-012-0272-z. View

Weston S, Coleman C, Haupt R, Logue J, Matthews K, Li Y . Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV . J Virol. 2020; 94(21). PMC: 7565640. DOI: 10.1128/JVI.01218-20. View

Al-Bari M . Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015; 70(6):1608-21. PMC: 7537707. DOI: 10.1093/jac/dkv018. View

Gabriel S, Michaud K . Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009; 11(3):229. PMC: 2714099. DOI: 10.1186/ar2669. View

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

Naarding M, Baan E, Pollakis G, Paxton W . Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007; 4:6. PMC: 1796897. DOI: 10.1186/1742-4690-4-6. View

Fan H, Ma Z, Chen J, Yang X, Cheng J, Li Y . Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. Rheumatol Ther. 2016; 2(2):183-195. PMC: 4883261. DOI: 10.1007/s40744-015-0012-0. View

Ould Ahmedou Salem M, Mohamed Lemine Y, Mint Deida J, Ould Lemrabott M, Ouldabdallahi M, Ba M . Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania. Malar J. 2015; 14:39. PMC: 4318167. DOI: 10.1186/s12936-015-0563-0. View

10.

Kitchen A, Chiodini P . Malaria and blood transfusion. Vox Sang. 2006; 90(2):77-84. DOI: 10.1111/j.1423-0410.2006.00733.x. View

11.

Sciascia S, Hunt B, Talavera-Garcia E, Lliso G, Khamashta M, Cuadrado M . The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2015; 214(2):273.e1-273.e8. DOI: 10.1016/j.ajog.2015.09.078. View

12.

Azarian Moghadam H, Nateghpour M, Raeisi A, Motevalli Haghi A, Edrissian G, Farivar L . Monitoring the Response of to Chloroquine and Uncomplicated to Artesunate-fansidar Antimalarials in Southeastern Iran. Iran J Parasitol. 2018; 13(1):31-38. PMC: 6019585. View

13.

Katz S, Russell A . Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011; 23(3):278-81. DOI: 10.1097/BOR.0b013e32834456bf. View

14.

Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S . Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol. 1983; 64(Pt 5):1149-56. DOI: 10.1099/0022-1317-64-5-1149. View

15.

Helal G, Gad M, Abd-Ellah M, Eid M . Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016; 88(12):2170-2178. PMC: 7167065. DOI: 10.1002/jmv.24575. View

16.

Le Bras J, Durand R . The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol. 2003; 17(2):147-53. DOI: 10.1046/j.1472-8206.2003.00164.x. View

17.

Sundelin S, Terman A . Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002; 110(6):481-9. DOI: 10.1034/j.1600-0463.2002.100606.x. View

18.

Mallat J, Hamed F, Balkis M, Mohamed M, Mooty M, Malik A . Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. Medicine (Baltimore). 2020; 99(52):e23720. PMC: 7769326. DOI: 10.1097/MD.0000000000023720. View

19.

Antinori S, Galimberti L, Milazzo L, Corbellino M . Biology of human malaria plasmodia including Plasmodium knowlesi. Mediterr J Hematol Infect Dis. 2012; 4(1):e2012013. PMC: 3340990. DOI: 10.4084/MJHID.2012.013. View

20.

Valderramos S, Fidock D . Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci. 2006; 27(11):594-601. PMC: 2944664. DOI: 10.1016/j.tips.2006.09.005. View